MFG
NBIX icon

Merit Financial Group’s Neurocrine Biosciences NBIX Stock Holding History

Merit Financial Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.16M Sell
18,744
-2,648
-12% -$393K 0.02% 568
2026
Q1 		$2.82M Buy
21,392
+3,861
+22% +$512K 0.02% 555
2025
Q4 		$2.49M Buy
17,531
+2,905
+20% +$421K 0.02% 559
2025
Q3 		$2.05M Buy
14,626
+7,362
+101% +$998K 0.02% 564
2025
Q2 		$913K Buy
7,264
+3,111
+75% +$357K 0.01% 835
2025
Q1 		$459K Buy
4,153
+345
+9% +$43.7K 0.01% 972
2024
Q4 		$520K Buy
+3,808
New +$471K 0.01% 716
2023
Q4 		– Sell
-2,479
Closed -$279K – 810
2023
Q3 		$279K Buy
+2,479
New +$261K 0.01% 606

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Merit Financial Group's NBIX Position: Q2 2026 in Review

Merit Financial Group reduced its Neurocrine Biosciences (NBIX) stake by 12% in Q2 2026, selling an estimated $393K and leaving 18,744 shares worth $3.16M. The position accounts for 0.02% of the portfolio, ranked #568.

Merit Financial Group first reported a position in NBIX in Q3 2023 and has held it in 8 quarters since. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Merit Financial Group held 18,744 shares of Neurocrine Biosciences worth $3.16M as of Q2 2026.
  • Merit Financial Group sold 2,648 Neurocrine Biosciences shares in Q2 2026, an estimated $393K.
  • Neurocrine Biosciences made up 0.02% of Merit Financial Group's portfolio in Q2 2026, its #568 holding.
  • Merit Financial Group first reported a position in Neurocrine Biosciences in Q3 2023 and has held it in 8 quarters since.
  • 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Merit Financial Group's 13F filing for Q2 2026, filed 17 Jul 2026.